Peptides have moved from obscure research compounds to one of the most actively studied categories in applied biology, sports science, and longevity research. Whether you are a first-time researcher trying to understand basic reconstitution steps or an experienced biohacker optimizing a multi-peptide stack, having a reliable, science-grounded resource makes the difference between a productive protocol and a costly mistake. This complete peptide reference guide covers everything you need: compound classifications, mechanism of action, evidence quality, dosing methodology, storage best practices, vendor evaluation, legal considerations by region, and advanced stacking logic. Each section is built around real research data, not marketing copy, so you can make informed, rational decisions at every stage of your work.

Introduction to Peptide Therapy

Peptides are short chains of amino acids, typically between 2 and 50 residues, that act as signaling molecules throughout the body. Unlike full proteins, their compact size allows them to interact with highly specific receptors, produce targeted physiological effects, and clear the bloodstream relatively quickly. This selectivity is exactly what makes them so interesting to researchers studying tissue repair, hormonal optimization, immune modulation, and metabolic function.

The term "peptide therapy" broadly refers to the intentional administration of exogenous peptides to influence biological pathways. In clinical medicine, peptide-based drugs have existed for decades. Insulin is itself a peptide hormone. Synthetic analogs like oxytocin, vasopressin, and various GLP-1 receptor agonists are FDA-approved treatments. However, the research chemical market has expanded far beyond pharmaceutical peptides, introducing dozens of compounds synthesized for experimental purposes that exist in a legal and regulatory gray zone.

This peptide reference guide is designed to bridge the gap between available scientific literature and practical application. Throughout the article, you will find co-referenced concepts, specific compound profiles, and protocol logic that reflects the current state of evidence, honest about its limitations where animal data is the primary source and more confident where human clinical trials exist.

Peptide Reference Guide: Categories and Their Uses

A functional peptide classification system helps researchers match the right compound to the right research objective. Peptides can be organized by structure, mechanism, or therapeutic category. In practice, most researchers use a hybrid approach, grouping compounds by their primary biological target.

Growth Hormone Secretagogues (GHS)

This is one of the most extensively researched peptide categories. Growth hormone secretagogues stimulate the pituitary gland to release endogenous growth hormone through two primary mechanisms: GHRH receptor agonism and ghrelin receptor agonism.

Sermorelin is a GHRH analog consisting of the first 29 amino acids of endogenous growth hormone-releasing hormone. It stimulates natural pulsatile GH release and has been used in FDA-approved formulations for GH deficiency diagnosis and pediatric growth disorders. Its relatively short half-life encourages physiological release patterns rather than supraphysiological surges.
CJC-1295 is a longer-acting GHRH analog available in two formulations: CJC-1295 with DAC (Drug Affinity Complex), which binds to albumin and extends half-life to approximately 8 days, and CJC-1295 without DAC (also known as Modified GRF 1-29), which has a half-life closer to 30 minutes and produces more natural pulsatile patterns. The DAC variant produces a prolonged GH bleed that some researchers find counterproductive when trying to mimic physiological rhythms.
Ipamorelin is a selective growth hormone-releasing peptide (GHRP) that acts on ghrelin receptors. Its defining characteristic is a low side effect profile compared to older GHRPs like GHRP-6. It does not significantly elevate cortisol or prolactin at standard doses, making it a preferred GHRP for longer protocols.

The CJC-1295 and Ipamorelin stack is one of the most commonly researched combinations in the GHS category. When a GHRH analog and a GHRP are combined, their mechanisms act on different receptor systems simultaneously, producing an additive or synergistic increase in GH release. This pharmacodynamic overlap principle is central to stacking rationale, covered in more detail later in this guide.

Tissue Repair and Recovery Peptides

BPC-157, or Body Protection Compound, is a 15-amino-acid peptide derived from a protein found in gastric juice. Animal research has documented accelerated healing of tendons, ligaments, muscle, and gastrointestinal tissue. Its proposed mechanisms include upregulation of growth factor receptors, promotion of angiogenesis, and modulation of nitric oxide pathways. There are no large-scale human clinical trials published at the time of this writing, though several case reports and small studies exist.

TB-500, the synthetic form of the active region of Thymosin Beta-4, promotes actin polymerization, cell migration, and angiogenesis. In animal models, it has shown benefit for cardiac tissue repair and wound healing. BPC-157 and TB-500 are often discussed together because of their complementary mechanisms. BPC-157 tends to show stronger localized effects on musculoskeletal tissue, while TB-500 appears to have broader systemic distribution. Stacking both compounds is a common research protocol for injury recovery models.

Skin and Collagen Peptides

GHK-Cu, a copper peptide complex, has one of the more robust bodies of evidence in the cosmetic and dermatology research space. Studies have demonstrated its role in stimulating collagen synthesis, promoting wound contraction, and exhibiting antioxidant effects. Its small size allows topical penetration, and both topical and injectable forms are studied. GHK-Cu also appears to upregulate genes associated with tissue remodeling, making it relevant beyond purely cosmetic applications.

Research and Clinical Evidence Overview

Understanding the evidence hierarchy in peptide research is non-negotiable for responsible self-experimentation. The ladder runs from in vitro cell studies at the bottom, through animal models, small human trials, randomized controlled trials, and finally systematic reviews and meta-analyses at the top.

Most research chemicals in circulation today sit firmly in the animal study tier. BPC-157 has compelling rodent data but virtually no randomized human clinical trials. TB-500 is in a similar position. GHRPs like Ipamorelin have more human data, largely because pharmaceutical companies investigated them as potential therapeutics before development was paused or abandoned. Sermorelin has the strongest clinical evidence base among GH secretagogues, having been formally approved and studied in human populations.

The National Institutes of Health maintains a database of registered clinical trials at ClinicalTrials.gov, where researchers can verify the current status of peptide-related human studies. This is a useful primary source for checking whether a compound you are researching has moved into human trial phases.

When evaluating any peptide protocol, ask three questions: Is this effect documented in humans or only animals? What dose was used in the relevant study, and does it translate to the dose commonly circulated in research communities? Were there adverse effects observed in studies that are being underreported in popular forums?

Peptide Reference Guide: Dosing and Reconstitution Protocols

Reconstitution methodology is one of the most practical skills in peptide research and also one of the most frequently mishandled by beginners. Lyophilized (freeze-dried) peptide vials require careful preparation to restore the compound to an injectable solution without degrading its potency.

Bacteriostatic Water Versus Sterile Water

The first decision in any reconstitution protocol is solvent selection. Bacteriostatic water, which contains 0.9% benzyl alcohol as a preservative, is the standard choice for peptide reconstitution. The benzyl alcohol inhibits bacterial growth, extending the usable shelf life of the reconstituted solution to approximately 28 to 30 days when refrigerated. Sterile water contains no preservatives and should only be used for single-dose preparations because it supports microbial growth once opened. For any researcher drawing multiple doses from a single vial over weeks, bacteriostatic water is the correct choice.

Step-by-Step Reconstitution Guide

Clean the tops of both the peptide vial and the bacteriostatic water vial with an alcohol swab. Allow both to air dry for 30 seconds.
Draw the desired volume of bacteriostatic water into an insulin syringe. The volume depends on your target dose concentration. A common starting point is 1 to 2 mL of bacteriostatic water per vial.
Insert the needle into the peptide vial at an angle and allow the water to run down the inside wall of the vial rather than blasting it directly onto the lyophilized powder. Direct pressure can shear peptide bonds and reduce potency.
Do not shake the vial. Gently swirl or roll it between your palms until the powder is fully dissolved. Vigorous agitation denatures peptides.
Visually inspect the solution. It should be clear and colorless or very lightly tinted depending on the compound. Cloudiness, particulates, or unusual color changes are red flags.
Store the reconstituted vial in a refrigerator at 2 to 8 degrees Celsius, protected from light.

Calculating Doses and Drawing Accurate Volumes

Accurate dosing requires understanding the relationship between the total peptide mass in a vial, the volume of bacteriostatic water added, and the resulting concentration. The formula is straightforward: divide the total mass of peptide (in micrograms or milligrams) by the total volume of solvent added (in milliliters) to get concentration per milliliter.

For example, a 5 mg vial of Ipamorelin reconstituted with 2 mL of bacteriostatic water yields a concentration of 2.5 mg per mL, or 2500 mcg per mL. A target dose of 200 mcg requires drawing 0.08 mL (8 units on a 100-unit insulin syringe). Documenting these calculations in a research log before every session reduces dosing errors significantly.

When switching between vials of different concentrations, recalculate completely rather than assuming the same draw volume applies. A measurement error at this stage compounds across every dose in a protocol cycle.

Storage and Stability Guidelines

Peptide degradation is a function of temperature, light exposure, moisture, and pH. Understanding the specific vulnerabilities of lyophilized versus reconstituted peptides allows researchers to preserve compound integrity from purchase through final use.

Lyophilized Peptide Storage

Unopened lyophilized peptide vials are considerably more stable than reconstituted solutions. Most lyophilized peptides remain stable for 12 to 24 months when stored at minus 20 degrees Celsius in a standard laboratory freezer. Refrigerator storage at 2 to 8 degrees Celsius is acceptable for periods up to 3 to 6 months for most compounds, though this varies by peptide. Room temperature storage accelerates degradation and should be avoided except during the brief handling window of reconstitution.

Freeze-thaw cycles damage peptide structure progressively. Researchers should avoid repeatedly freezing and thawing the same vial. If long-term storage is planned, aliquoting the lyophilized powder into multiple smaller vials before any reconstitution preserves stability and reduces waste.

Reconstituted Peptide Storage

Once reconstituted with bacteriostatic water, peptide solutions should be stored at 2 to 8 degrees Celsius and used within 28 to 30 days. Light degrades several peptides, particularly those containing tryptophan or tyrosine residues, so amber vials or foil wrapping add meaningful protection. Reconstituted solutions should never be frozen, as ice crystal formation physically disrupts the peptide structure and causes irreversible aggregation in many compounds.

Safety Protocols and Side Effect Management

Safety in peptide research begins with sourcing and extends through every step of preparation and administration. No protocol design compensates for starting with an impure or mislabeled compound. The sections below outline both general safety principles and compound-specific considerations that researchers should integrate into their standard operating procedures.

Injection Site Hygiene and Administration Technique

Subcutaneous injection is the most common administration route for research peptides. The abdomen, outer thighs, and lateral deltoid region offer accessible subcutaneous tissue with consistent absorption. Rotating injection sites prevents localized tissue irritation and lipohypertrophy, a hardening of subcutaneous tissue that develops from repeated injections at the same site.

Sterile technique requires cleaning the injection site with an alcohol swab, using a new needle for every injection, and disposing of sharps in an approved sharps container. Reusing needles introduces infection risk and causes burring of the needle tip, which increases injection discomfort and tissue trauma.

Common Side Effects by Category

Growth hormone secretagogues as a category share several predictable side effects that are dose-dependent and generally transient. Water retention, particularly in the extremities, is common in the first weeks of GH-stimulating protocols as IGF-1 levels rise and sodium retention increases. Carpal tunnel-like tingling in the hands is a related phenomenon. Hunger stimulation is notable with GHRP compounds that act on ghrelin receptors; Ipamorelin is milder in this regard than GHRP-6 or GHRP-2.

BPC-157 has an unusually clean side effect profile in animal literature, with few documented adverse effects even at elevated doses in rodent models. However, the absence of documented adverse effects in animal studies does not confirm human safety, and researchers should apply the precautionary principle accordingly. Some users report mild nausea following subcutaneous administration, which typically resolves by adjusting injection timing relative to meals.

Any unexpected systemic reaction, including fever, significant swelling beyond the injection site, or cardiovascular irregularity, warrants immediate cessation of the protocol and medical evaluation. Researchers should maintain detailed logs that allow them to correlate symptom onset with specific compounds, doses, and timing.

Vendor Evaluation and Quality Assessment

The quality variance across peptide vendors is one of the most underappreciated risks in independent research. Unlike pharmaceutical-grade compounds manufactured under FDA oversight, research chemical peptides are produced by a fragmented supply chain with inconsistent quality controls. A vial labeled as 5 mg of BPC-157 may contain anywhere from the correct dose of pure compound to a diluted product, a mislabeled compound, or in the worst cases, a contaminated preparation.

Third-Party Testing as a Baseline Requirement

The minimum quality standard any researcher should require from a vendor is third-party certificate of analysis (COA) documentation from an independent analytical laboratory. A legitimate COA will specify the testing method used, typically high-performance liquid chromatography (HPLC) for purity and mass spectrometry for identity confirmation. Purity values above 98% are the research standard. Vendors who cannot provide COAs on request, or who supply only in-house testing documents without third-party verification, should be disqualified.

COA dates matter. A certificate issued two years ago does not verify the quality of a batch produced last month. Reputable vendors test each production batch separately and make batch-specific COAs available, usually matched to a lot number printed on the vial label.

Additional Vendor Quality Indicators

Beyond COA documentation, several secondary signals help distinguish higher-quality vendors. Transparent sourcing information about synthesis facilities and peptide grade (research grade versus pharmaceutical grade) reflects operational seriousness. Vendors who publish detailed compound information, including sequence confirmation and storage recommendations, demonstrate product knowledge that correlates with quality control investment. Community reputation across multiple independent research forums, cross-referenced over time, provides ground-level feedback that marketing materials cannot replicate.

Pricing is a secondary signal rather than a primary one. Extremely low pricing can reflect corner-cutting in synthesis or testing, but high pricing alone does not guarantee quality. Use COA documentation as the primary filter, and treat pricing as context for interpreting it.

Legal Status and Regulatory Considerations

The legal status of research peptides varies substantially by country and, in some cases, by jurisdiction within a country. Researchers must understand the regulatory framework governing their specific location before acquiring or working with any compound in this category.

United States Regulatory Framework

In the United States, research peptides that are not FDA-approved drugs occupy an ambiguous legal space. They can be legally sold and purchased for research purposes only, meaning use in laboratory settings and not for human consumption. The FDA has the authority to take enforcement action against vendors marketing compounds for human use, and has done so with increasing frequency since 2020. The "for research use only" designation is not a legal shield for personal administration; it is a specific claim about intended use that must be genuine to have legal standing.

Sermorelin is a notable exception. It has FDA-approved status in specific formulations and can be legally prescribed by licensed physicians for qualifying conditions. CJC-1295, Ipamorelin, BPC-157, and TB-500, by contrast, have no FDA-approved status and are not legal for prescription or clinical use in the United States at the time of this